| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 35.53 | 13.4% |
| Total Income | 37.58 | 12.4% |
| Expenditure | 27.40 | 11.9% |
| PBT | 10.18 | 14.0% |
| Net Profit | 7.79 | 8.7% |
| OPM | 25.21% | 1.24pp |
| NPM | 20.73% | 0.84pp |
| EPS | 17.66 | 8.7% |
Jenburkt Pharmaceuticals Ltd. Announces Q1 2025 Financial Results with 18.2% YoY Revenue Growth
12 Aug 2025 · 12 Aug 2025, 05:44 pm
Summary
Jenburkt Pharmaceuticals Ltd. has announced its Q1 2025 financial results, showing a 18.2% YoY revenue growth. The Audit Committee and Board of Directors have reviewed and approved the standalone unaudited financial results.
Key Highlights
- 1
Q1 2025 revenue growth of 18.2% YoY
- 2
Standalone unaudited financial results for the quarter from 1 April, 2025 to 30 June, 2025
- 3
The Board Meeting commenced at 02.30 p.m. (IST) and concluded at 5:15 p.m. (IST) on 12 August, 2025
Informational and educational content only. Not investment advice.